Living bio-drug therapies using mesenchymal stem cells and exosomes for mechanically ventilated patients with acute respiratory distress syndrome: A systematic review and meta-analysis

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 10

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Stem Cells

ISSN

1948-0210

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Stem Cells. Oct 26, 2025; 17(10): 111978
Published online Oct 26, 2025. doi: 10.4252/wjsc.v17.i10.111978

Full Size Figure Download Figure

Figure 2 The quality assessment of the included trials based on the Cochrane risk of bias tool 1. D: Domain.

Citation: Safwan M, Bourgleh MS, Al-Ruqi A, Shrebaty O, Almujaydil F, AlOthaim B, AlRashidi N, Haider KH. Living bio-drug therapies using mesenchymal stem cells and exosomes for mechanically ventilated patients with acute respiratory distress syndrome: A systematic review and meta-analysis. World J Stem Cells 2025; 17(10): 111978
URL: https://www.wjgnet.com/1948-0210/full/v17/i10/111978.htm
DOI: https://dx.doi.org/10.4252/wjsc.v17.i10.111978

Safwan M, Bourgleh MS, Al-Ruqi A, Shrebaty O, Almujaydil F, AlOthaim B, AlRashidi N, Haider KH. Living bio-drug therapies using mesenchymal stem cells and exosomes for mechanically ventilated patients with acute respiratory distress syndrome: A systematic review and meta-analysis. World J Stem Cells 2025; 17(10): 111978 [PMID: 41180212 DOI: 10.4252/wjsc.v17.i10.111978]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.